Recruiting

Genetic Polymorphisms

Sponsor:

University of British Columbia

Code:

NCT02322918

Conditions

Psychosis

Schizophrenia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Blood samples for whole genomic/transcriptomic sequencing

Study Details

Brief summary:

The purpose of this study is to determine if candidate polymorphisms in brain-derived neurotrophic factor (BDNF) and catechol-o-methyl transferase (COMT) are predictive of psychosis disorder severity, symptomology, and resolution in patients at BCPP. A secondary objective will be to form a biorepository of blood and saliva samples from patients at BCPP so that further genetic, proteonomic and pharmacogenomic studies may be done to gain insight into the genetic basis of differences in psychosis disorder presentation and manifestation, and differences in response to antipsychotic drug treatment.

Conditions

Psychosis

Schizophrenia

Study ID

NCT02322918

Start date

Jul, 2014

Status verified date

May, 2016

Completion date

Jul, 2018

Anticipated

Primary completion date

Jul, 2018

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Admission to BCPP.
  • Has provided written informed consent.

Exclusion Criteria:

  • None.

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants admitted to BCPP

Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing

Interventions

Blood samples for whole genomic/transcriptomic sequencing

Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.

Primary outcome measure

  • Creation of biorepository of blood samples for future genetic, proteonomic and pharmacogenomic studies. [ Time Frame: One visit during participant's stay at BCPP, an expected average of 6 months ]

Central Contacts and Locations

Central contacts

Delrae Fawcett, M.Sc.

604-875-2000delrae.fawcett@ubc.ca

Heidi Boyda, Ph.D.

604-875-2000heidi.boyda@ubc.ca

Locations

University of British Columbia Hospital - BC Psychosis Program

Recruiting

Vancouver, British Columbia, Canada, V6T 2A1

Contacts

Delrae Fawcett, M.Sc.

604-875-2000delrae.fawcett@ubc.ca

Heidi N Boyda, Ph.D.

604-875-2000heidi.boyda@ubc.ca

Principal Investigator:

Alasdair M Barr, Ph.D.

More Information

Sponsor

University of British Columbia

Last update posted

Jun 1, 2016

Last verified

May, 2016

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of British Columbia on 2016-06-01.